H. Thomas Watkins

Tom has served on the board of directors since April 2014. In his most recent role, he was director, president and chief executive officer of Human Genome Sciences (HGS) from 2004 to 2012 when HGS was acquired by GlaxoSmithKline. Before leading HGS, Tom spent nearly 20 years in senior roles at Abbott and its affiliates in the United States and Asia, most recently serving as the president of TAP Pharmaceutical Products, Inc., which was jointly owned by Abbott and Takeda Pharmaceutical Company, Inc. During his tenure, he led the growth of TAP from approximately $2 billion to more than $4 billion in annual revenue. Tom began his career in 1974 with Arthur Andersen & Co. From 1979 to 1985, he was a management consultant with McKinsey and Company, Inc., working with multinational companies in the United States, Europe and Japan.

Tom holds a bachelor’s degree from the College of William & Mary, and a Master of Business Administration from the University of Chicago Graduate School of Business. Currently, he is the chairman of the board of directors of Vanda Pharmaceuticals, Inc. He is also a member of the board of directors of the Biotechnology Innovation Organization (BIO) and a member of the board of visitors of the College of William & Mary.